Skip to main content
Fig. 1 | BMC Proceedings

Fig. 1

From: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

Fig. 1

Steps for switching from baseline treatment to the CNIC-polypill in secondary prevention of cardiovascular disease in patients treated with multiple drugs/pills for their associated cardiovascular risk factors and comorbidities. ASA, acetylsalicylic acid; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; PCSK9i, proprotein convertase subtilisin-kexin type 9 inhibitor. Source: Coca J Hypertens. 2020;38(10):1890–98 [11]. Reproduced with permission

Back to article page

BMC Proceedings

ISSN: 1753-6561

Contact us